



Press release |

IBA to Distribute RadCheck and BrachyCheck Software Solutions for Enhanced Quality Assurance in Radiation Therapy

Worldwide distribution agreement with Axios Oncology addresses need for increased patient safety

Schwarzenbruck, Germany, and London, England, May 9, 2011 – [IBA](#) announced today at the European Society for Therapeutic Radiology and Oncology conference that it has signed an agreement with Axios Oncology for the worldwide distribution of Axios Oncology's radiation therapy software solutions, RadCheck and BrachyCheck. With the addition of this software suite to its product portfolio, IBA offers enhanced solutions for radiation therapy to address quality assurance and patient safety needs.

RadCheck and BrachyCheck are software solutions for standalone dose verification of independent monitor units calculations in external beam radiation therapy and of calculations in brachytherapy. The software suite provides simple tools that enable pre-treatment verification of plans and thereby reinforces hospital and clinic quality assurance programs. IBA will distribute the products to its customers and to radiation therapy vendors worldwide through its international sales and marketing network.

"There is an increasing awareness from both patients and oncologists about the aspect of patient safety and how secondary checks in radiation therapy can be a crucial supporting element in avoiding errors," said Dr. Juan Carlos Celi, vice president strategic business development, IBA. "IBA provides different solutions to ensure quality and safety of treatment delivery in radiation oncology and, by making additional ones more widely available to the marketplace, reinforces its commitment to improving patient safety on a global scale."

###

About IBA

IBA's dosimetry activities offer a full range of innovative solutions for radiotherapy, radiodiagnostics, calibration service and imaging markers. Its measuring instruments and software enable medical physicists and radiologists to perform the necessary quality assurance and calibration procedures.

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Please visit www.iba-dosimetry.com and www.iba-worldwide.com for more information about IBA.

Contact:

Ralf Schira
Vice President Marketing
IBA Dosimetry GmbH
Mobile: +49 172 865 17 29
Ralf.schira@iba-group.com